MedTrace Logo

A Study of Regorafenib in Advanced Pancreatic Cancer Patients

NCT02080260 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-04-21

Study results available
· View outcomes & findings →

Summary

This study tests regorafenib as a single agent in the treatment of metastatic pancreatic cancer patients who have progressed after prior chemotherapy with gemcitabine. The prognosis for these patients is particularly grim, no other standard treatment options exist, and novel approaches are desperately needed.

Conditions

Interventions

DRUG

regorafenib

Single agent drug therapy with regorafenib

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • John S Salmon, MD · Atrium Health Levine Cancer Institute

  • Edward Kim, MD · Atrium Health Levine Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-06
Primary Completion
2017-06-28
Completion
2017-06-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02080260 on ClinicalTrials.gov